Table 1.

Oral HPV prevalence (among valid tests at baseline) by HIV status and sex. The male and female columns may not add up to the total because of participants who indicated “other” sex or did not answer. The p-value is for the test of proportions between all HIV+ and all HIV- individuals, except for the number of genotypes, which is for a chi-square test. Genotype-specific prevalence is included in the supplementary material (Table S5).

	HIV + (N = 245)						HIV -(N = 198)						p-value
	All (N = 245)		Male (N = 155)		Female (N = 86)		All (N = 198)		Male (N = 83)		Female (N = 115)
	% HPV+	N	% HPV+	N	% HPV+	N	% HPV+	N	% HPV+	N	% HPV+	N
Any tested: 6, 11, 16, 18, 31, 33, 35 39, 45, 51, 52, 56, 58, 59, 66, 68, 73, 90	23%	56	27%	42	15%	13	10%	19	16%	13	5%	6	< 0.001
Number of genotypes detected in same saliva sample													0.06
1 genotype	14%	35	17%	27	8%	7	9%	17	14%	12	4%	5
2 or more genotypes	9%	21	10%	15	7%	6	1%	2	1%	1	1%	1
Clinical test high-risk: 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68	18%	44	23%	35	9%	8	7%	13	12%	10	3%	3	< 0.001
IARC Group 1 and 2A: 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68	16%	38	20%	31	8%	7	5%	9	8%	7	2%	2	< 0.001
Gardasil 9 vaccine genotypes: 6, 11, 16, 18, 31, 33, 45, 52, 58	15%	37	19%	29	9%	8	6%	11	10%	8	3%	3	0.001
Gardasil 9 vaccine high-risk genotypes: 16, 18, 31, 33, 45, 52, 58	11%	28	15%	23	6%	5	4%	7	7%	6	1%	1	0.002
Non-vaccine high risk genotypes: 35, 39, 51, 56, 59, 66, 68	10%	25	13%	20	5%	4	4%	7	6%	5	2%	2	0.007
Gardasil vaccine genotypes: 6, 11, 16, 18	10%	25	12%	19	7%	6	5%	10	8%	7	3%	3	0.05
Genotypes 16, 18	7%	16	8%	13	3%	3	3%	6	6%	5	1%	1	0.09
Genital warts genotypes: 6, 11	5%	12	5%	8	5%	4	2%	4	2%	2	2%	2	0.11